Our Mission, Our Story

Our Mission

Create a new standard of care for a large spectrum of heart failure patients by introducing breakthrough implantable circulatory support solutions that restore a normal life with minimal side effects.

Our Story

CorWave is a high-growth company founded in 2011 by the incubator MD Start and supported by renowned investors. We raised more than 35 million euros in funding, and the company employs more than 50 people.

CorWave has won numerous awards and competitions. In 2016 CorWave won phase 1 of the Worldwide Innovation Challenge (Concours Mondial d’Innovation – CMI) for the NovaPulse project. In 2017, this project also won phase 2 of the CMI competition. In the same year, CorWave received the Deloitte Technology Fast 50 Biotech Future Award and in 2018 a grant for the Calypso project as part of the Program d’Investissements d’Avenir (PIA) operated by Bpifrance.


Invention of wave membrane technology by Jean-Baptiste Drevet, he collaborates with the CNRS and creates AMS R&D


Creation of the company CorWave SAS by the incubator MD Start and exclusive license agreement with AMS R&D


CorWave joins Agoranov Incubator

First presentation at a scientific congress of cardiac surgery


€ 3.3M in Series A financing


CorWave joins Paris Biotech Santé incubator


Participates in the Worldwide Innovation Challenge, wins phase 1 for the NovaPulse project (Nemo development)

€15.5M in series B financing


Participates in the Worldwide Innovation Challenge, wins phase 2 for the NovaPulse project

Receives the Deloitte Technology Fast 50 Biotech Future award

CorWave joins BPI Hub HealthTech


Nominated for “Trophée des Futures Licornes”  award

Receives Audience Award for SNITEM innovative start-ups

Receives a PSPC grant by BPI for the Calypso project


Selected among KPMG Tech Pulse 40 companies

Receives “Trophée de l’embarqué” award for healthcare category

We have over 50 employees, hailing from around the globe.